29 October 2003

Director of Operations

Syarikat Megah Pharma & Vaccines (M) Sdn Bhd
Suite E1103, Block E
Pusat Dagangan Phileo Damansara 1
46350 Petaling Jaya


Authorisation for exploitation of patented invention in Malaysia

By virtue of Section 84(1)(a), Patents Act 1983, Syarikat Megah Pharma &
Vaccines (M) Sdn Bhd (Company No: 552048-H) is hereby authorised to
exploit patented inventions for the following drugs:

i.    Didanosine 100mg tablets produced by Bristol-Myers Squibb;
ii.    Didanosine 25mg tablet produced by Bristol-Myers Squibb;
iii.    Zidovudine 100 mg capsule produced  by GlaxoSmithKline; and
iv.    Lamivudine 150mg + Zidovudine 300mg tablet produced by GlaxoSmithKline.

2.    The authorisation is valid for two years, commencing November 1 2003.
It is subject to the following conditions:

i.    the authorisation shall be limited to the importation of the above
listed drugs from Cipla, India;

ii.    the drugs to be imported shall only be for supply to government
(public) hospitals;

iii.    importation of the said drugs shall be subject to the terms and
conditions as specified by the Ministry of Health, Malaysia;

iv.    the quantity to be imported shall be as specified by the Ministry of
Health, Malaysia;

v.    all packaging of the drugs shall be labelled with the words
“KEMENTERIAN KESIHATAN MALAYSIA” (Ministry of Health, Malaysia);

vi.    the name (brand), shape or colouring of the tablets or capsules
shall be differentiated from that of the patented products in Malaysia;

vii.    the company shall be required to register the sale in the scheduled
poisons register (please check this – think it refers to the Scheduled
Poisons regulations);

viii.    the ceiling price for the said drugs to be supplied to the
Ministry of Health, Malaysia shall not exceed the following:

(a) Didanosine 100 mg tablet        -     RM74.58 (per box of 60 tablets)

(b) Didanosine 25 mg tablet        -    RM22.80 (per box of 60 tablets)

(c) Zidovudine 100 mg capsules     -    RM5.89 (one set of 10 capsules)

(d) Lamivudine 150mg +
  Zidovudine 300mg tablet        -    RM153.50 (per box of 60 tablets)

ix.    Payment of compensation shall be made to the patent holder(s) within
2 months of each import of the said drugs. The rate of compensation is
to be determined at a later date.

3. The above terms and conditions may be amended or varied as deemed

4. The authorisation may be terminated at any time in the event of
non-compliance with the terms and conditions as specified above.

                     (Minister of Domestic Trade and Consumer Affairs,

Return to: CPTech Home -> Main IP Page -> IP and Healthcare -> Malaysia Page